论文部分内容阅读
目的评估广州地区人群中人腺病毒5型(HAdV-5)中和抗体阳性率情况。方法采用以β-半乳糖苷酶(LacZ)为报告基因,结合CMV启动子的人重组腺病毒5型载体,运用化学发光法,检测209份免疫功能正常的成人血清样本中HAdV-5的中和抗体。结果 HAdV-5中和抗体的阳性率为82.3%(172/209)。HAdV-5中和抗体在<1:20(低滴度)、1:40-1:160(中滴度)、1:320-1:1280(高滴度)、>1:1280(超高滴度)时均能检测到,而且随着滴度的增加,阳性率逐渐升高。在20～40岁时HAdV-5中和抗体阳性率最高,在<20岁时HAdV-5阳性率最低。结论广州地区人群中针对HAdV-5的先存中和抗体阳性率高,应用基于该种DNA病毒作为载体进行基因疫苗及基因治疗的研究时,具有一定的局限性。
Objective To evaluate the positive rate of neutralizing antibodies against human adenovirus type 5 (HAdV-5) in Guangzhou population. Methods Chemiluminescence was used to detect the expression of HAdV-5 in 209 serum samples from immunocompetent adults with LacZ as reporter gene and CMV promoter combined with human recombinant adenovirus type 5 vector And antibodies. Results The positive rate of HAdV-5 neutralizing antibody was 82.3% (172/209). HAdV-5 neutralizing antibodies are stable at <1:20 (low titer), 1:40-1: 160 (medium titer), 1: 320-1: 1280 (high titer),> 1: 1280 Titers) were detected, and with the increase of titer, the positive rate gradually increased. The positive rate of HAdV-5 neutralizing antibody was the highest between the ages of 20 and 40, with the lowest positive rate of HAdV-5 at <20 years of age. Conclusions The positive rate of pre-existing neutralizing antibody against HAdV-5 in Guangzhou population is high. Therefore, the study on gene vaccine and gene therapy based on this DNA virus has some limitations.